March 17, 2010
Astellas Launches Proxy Battle
You'll remember that Astellas made a hostile offer for OSI Pharmaceuticals earlier in the month. Along with their offer, they sued in Delaware to get the OSI board to consider the offer. Well, the board has considered the offer ($52/sh cash, a 40% premium) and has rejected it. Here's part of their statement:
"After carefully analyzing and considering Astellas' offer, the Board has unanimously concluded that the offer does not fully reflect OSI's fundamental, intrinsic value. We believe that OSI is a unique asset - the only profitable, mid-cap biotech company with a growing, high quality and fully integrated oncology franchise and a strong diabetes and obesity franchise which also has a proven track-record of success. The OSI Board takes its fiduciary duties seriously and will continue to do what's right for OSI stockholders. In that regard, the Board of Directors has instructed OSI management, with the assistance of the Company's financial advisors, to contact appropriate third parties in order to explore the availability of a transaction that reflects the full intrinsic value of the Company.".
The full text of the OSI board's letter to shareholders can be found here.
TrackBack URL for this entry:
Listed below are links to weblogs that reference Astellas Launches Proxy Battle:
Seems it becomes obvious that giant corporations are now takin over the world.
Posted by: Proxy Yard | May 10, 2010 7:57:19 PM